Earlier this year results from the TERRAIN trial reported that adding enzalutamide (Xtandi) to LHRH agonist therapy was more effective than adding the antiandrogen bicalutamide in men with metastatic, castration-resistant prostate cancer ( M1 CRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: anti-androgen, bicalutamide, castration-resistant, enzalutamide, STRIVE | 1 Comment »
